Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Observational case-control study in a retrospective cohort of patients with stage II or III colorectal cancer undergoing scheduled surgery.
Observational case-control study in a retrospective cohort of patients with stage II or III colorectal cancer undergoing scheduled surgery. Period January 2010-December 2014. Patients must have had at least 5 years of follow-up to define disease-free survival. From the cohort of patients previously studied in our center by immunohistochemistry, 31 we will select 10 cases with recurrence by random sampling and we will match 10 controls by leveling the propensity score (propensity score matching).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients with tumor recurrence |
| ||
| patients with-out tumor recurrence |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Assess the difference in MOR-1 expression between healthy and tumor tissue | Other | Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery. |
| Measure | Description | Time Frame |
|---|---|---|
| MOR-1 expression by polymerase chain reaction (RT-qPCR) in tumor tissue and adjacent healthy tissue. | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Cancer-free survival 5 years after surgery (disease-free survival-DFS). | Day 1 | |
| Degree of MOR-1 activation measured by immunohistochemistry through cAMP and PKA levels. | Day 1 | |
| Measure | Description | Time Frame |
|---|---|---|
| Use of halogenated vs intravenous hypnotic agent | Day 1 | |
| Carcinoembryonic antigen | Day 1 | |
| Cancer antigen |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients undergoing scheduled colorectal surgery for stage II and III primary colorectal cancer during the period 01/01/2010 and 12/31/2014.
Not provided
Not provided
Not provided
Not provided
|
| MOR-1 expression by immunohistochemistry in tumor tissue and adjacent healthy tissue. |
| Day 1 |
| Day 1 |
| Neoadjuvant or adjuvant chemotherapy or radiation therapy | Day 1 |
| Surgery time | Day 1 |
| Surgery date | Day 1 |
| Hospital discharge | Day 1 |
| Surgery complications | Day 1 |
| Type of surgery | Day 1 |
| ASA test | Day 1 |
| Concomitant Diseases | Day 1 |